Guest guest Posted June 30, 2000 Report Share Posted June 30, 2000 Over 50,000 American women have hysterectomies each year. The leading cause of a hysterectomy is fibroid tumors. There’s a drug out there that may help shrink fibroids and possibly help prevent so many women from undergoing such invasive, life-changing surgery. This drug is called mifepristone, formerly known as RU-486. Some of you may know mifepristone as the “abortion pill,” but you may not be aware that there are so many more possible medical breakthroughs associated with this drug. Mifepristone may be approved in September 2000, but the FDA is currently discussing restrictions on the drug's distribution that may severely limit women's access to it. The FDA is reportedly considering onerous and medically unnecessary restrictions that could drastically limit its distribution, possibly even threaten the safety of physicians, and ultimately derail the development of the drug's non-abortion indications such as ovarian cancer, uterine fibroid tumors, meningioma (brain tumors), and endometriosis. Mifepristone, which has been used by millions of women throughout the majority of the European Union as well as China, Israel, Switzerland and other parts of the world, is a safe and effective method of early abortion that would be a historic milestone for women's health care. In 1996, the FDA already determined that mifepristone is safe and effective. Why are American women still waiting for it today? To learn more about this issue and how to support FDA approval of mifepristone without restrictions, TAKE ACTION NOW to help further medical advances for women: www.feminist.org/action/1_action.html Send this to all your friends and together we can urge the FDA to make this drug widely available. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.